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Abstract
Background:  Although colorectal cancer death rates have been declining, this trend is not
consistent across all ethnic groups. Biological, environmental, behavioral and socioeconomic
explanations exist, but the reason for this discrepancy remains inconclusive. We examined the
hypothesis that improved cancer screening across all ethnic groups will reduce ethnic differences
in colorectal cancer survival.
Methods: Through the Hawaii Tumor Registry 16,424 patients diagnosed with colorectal cancer
were identified during the years 1960–2000. Cox regression analyses were performed for each of
three cohorts stratified by ethnicity (Caucasian, Japanese, Hawaiian, Filipino, and Chinese). The
models included stage of diagnosis, year of diagnosis, age, and sex as predictors of survival.
Results: Mortality rates improved significantly for all ethnic groups. Moreover, with the exception
of Hawaiians, rates for all ethnic groups converged over time. Persistently lower survival for
Hawaiians appeared linked with more cancer treatment.
Conclusion: Ethnic disparities in colorectal cancer mortality rates appear primarily the result of
differential utilization of health care. If modern screening procedures can be provided equally to all
ethnic groups, ethnic outcome differences can be virtually eliminated.
Background
After lung, prostate, and breast cancer, colorectal cancer
ranks as a leading source of cancer mortality.[1] National-
ly, although death rates have been declining since the
mid-1980s, this trend is not consistent across all ethnic
groups.[2] Specifically, in the past 10 years the death rate
for Caucasians has been decreasing at nearly twice the rate
as that for African Americans, and for Native Americans
the rate has actually been increasing.[3,4] Among Asian
ethnic groups, Chinese and Filipinos suffer a higher death
rate than do the Japanese.[5] These ethnic disparities ap-
pear largely driven by differential stage distribution (e.g.,
more advanced stage cases at presentation). Underutiliza-
tion of cancer screening appears a key factor.[6] However,
studies have found that even after controlling for stage at
diagnosis, significant ethnic differences remain.[7]
How can one explain cancer survival differences that per-
sist after adjustment for stage? Biological theories suggest
that members of certain ethnic groups are genetically
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predisposed to more aggressive forms of the disease, differ
in host-tumor interactions, or are more likely to have con-
tributing comorbid conditions. Wudel et al. (2002) re-
cently reported that colorectal cancer survival differences
between Caucasians and African Americans could not be
explained by measurable differences in treatment.[8]
Neuhausen has proposed a multi-factorial biology-utiliza-
tion model.[9] Environmental theories propose that be-
havioral or socioeconomic factors leading to differential
utilization of medical care are responsible. Varying utiliza-
tion of, as well as access to health care has been reported
as an explanation. [10–12] Schrijvers et al. (1997) have
described a relation between socioeconomic status and
comorbidity.[13] Evidence of interaction between age and
socioeconomic status has also been reported.[14]
Hawaii's diverse ethnic composition combined with its
long-standing statewide cancer registry, the Hawaii Tumor
Registry (HTR), offer an ideal setting for examining ethnic
differences in cancer survival. Previous research has docu-
mented significant survival disparities among the major
ethnic groups (Caucasian, Japanese, Hawaiian, Filipino,
and Chinese) in the state. In 1978, Nomura et al. found
that Japanese patients had a nearly one-third higher sur-
vival rate than Caucasians.[15] Hirohata et al. (1977) de-
scribed better survival rates among Japanese and
Caucasians than among Filipinos and Hawaiians, even af-
ter adjusting for age, gender, and extent of disease at diag-
nosis.[16] Wegner et al. (1982) analyzed HTR data from
1960–1974 and found the same pattern of differences,
which also could not be explained by any of the available
covariates.[17]
The goal of the present study is to examine trends in recent
survival rates. The HTR data that was incorporated in the
Wegner (1982) study is still available as is more recent
data up to the year 2000, allowing for an examination of
survival patterns over time. Improved survival rates for
cancer patients were observed by Hinds et al. (1983) dur-
ing the years 1960–1974.[18] More recently, Maskarinec
et al. (1999) have described improved breast cancer sur-
vival among all ethnic groups for 1970–1990.[19] Also,
for the years 1995–1998 it was found that all ethnic dis-
parities in breast cancer survival were eliminated once
TNM Stage had been controlled.[20] These findings large-
ly fail to support purely biologic explanations of disparate
colorectal cancer survival. Differential utilization of
health care or access to health care appears more
important.
In Hawaii, the passage of time has brought general im-
provements in medical care and also narrowed disparities
in access to medical care. Utilization of screening proce-
dures continues to vary among ethnic groups, however. At
the onset of this study, we hypothesized that, over the past
30 years, improved cancer screening and treatment, as
well as better access to medical care across all ethnic
groups has both improved survival rates and reduced eth-
nic differences in colorectal cancer survival. We further
predicted that stage at diagnosis, age, and gender could ex-
plain most remaining survival differences, although we
questioned the role of other factors such as treatment uti-
lization and co-morbid disease.
Methods
Population and Sample
The population of Hawaii resides on seven islands with
80% on the island of Oahu and is estimated at 1.2 million
with approximately 580,000 women. [21] Close to 13%
of residents are 65 years and older and 40% are 40 years
and older. The majority of the population is of Asian and
Pacific Islander descent: 24.1% of the population in 1990
were Caucasian, 20.4% Japanese, 18.8% Native Hawaiian,
11.4% Filipino, 4.7% Chinese, and the rest other ethnic
groups. However, over the period of this study, differences
in age distribution within various ethnic groups in Hawaii
have driven some differences in the actual proportions of
individuals with cancer.
All data were ascertained through the Hawaii Tumor Reg-
istry (HTR), which provides population-based coverage of
all newly diagnosed cancer cases and subsequent follow-
up status for residents of Hawaii. The HTR was established
in 1960 and it became part of the Surveillance, Epidemi-
ology, and End Results (SEER) program in 1973. Quality
control reviews have shown that case-ascertainment
through HTR is virtually complete. Over 99% of cancer
cases reported to the registry are histologically con-
firmed[22] and less than 2% of cases are identified
through death certificates only. Whenever possible, the
HTR follows cases until death through regular linkages
with the Hawaii Department of Health's death records,
hospital-based registries, and additional sources of mor-
tality information. In accordance with SEER rules, less
than 5% of cases are lost to follow-up. The ethnicity clas-
sification in the HTR is based on self-reports by patients.
Information on the first course of treatment (surgery,
chemotherapy, radiation, and hormone therapy) is also
collected.[23]
From the HTR, all patients diagnosed with colorectal can-
cer (ICD-O-2 codes: C18.0-C18.9, C19.9, C20.9, C21.0-
C21.2, C21.8) from 1960–2000 were extracted. Of the
17,416 pathologically confirmed cases of invasive color-
ectal cancer, we excluded 757 patients who were not from
the five major ethnic groups (Caucasian, Japanese, Hawai-
ian, Filipino, and Chinese) and 235 patients for whom the
diagnosis date was unknown, leaving a total sample of
16,424 cases for analysis.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/5
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Statistical Analyses
Data were first examined for ethnic differences by cohort
across stage at diagnosis, age, sex, and cause of death using
the likelihood ratio χ2 statistic. This statistic is interpreted
in the same manner as the Pearson χ2, but provides great-
er precision. Next, the SAS procedure PHREG,[24] which
performs regression analyses based on the Cox propor-
tional hazards model, was used to conduct survival anal-
yses. As a test of the validity of the proportional hazards
assumption (that the hazard ratio does not change over
time), the Cox proportional hazards regression was per-
formed with a variable calculated as the mean deviated
natural log of time. Significance of this variable would im-
ply a violation of the proportional hazards assumption.
Survival (survivor function) estimates (used for figures)
were based on the fitted proportional hazards model, and
can be interpreted as the estimates for the survivor func-
tions controlling for the effects of the covariates.[25] The
same analyses were conducted in each of three separate
cohorts determined by the year of diagnosis: 1960–1974,
1975–1987, and 1988–2000. The years for the first cohort
were chosen to be consistent with the study conducted by
Wegner et al.[17]
The starting year for the third cohort was chosen as 1988
because that was the first year in which TNM staging data
(tumor size, node status, and metastases) became availa-
ble in the HTR.[26] With TNM stage data, a comparison
between the predictive value of this more comprehensive
form of staging (0, I, IIA, IIB, IIIA, IIIB, and IV) and the
SEER staging (local, regional, distant) could be made.[26]
The was accomplished by computing the increment in
model fit after the TNM stage variable had been added to
model containing the SEER stage variable. The likelihood
ratio statistic provides this information and is distributed
as chi-square, allowing for determination of statistical sig-
nificance. The years for the second cohort consisted sim-
ply of the years between cohorts one and three.
Within each cohort two sets of survival analyses were per-
formed: In the first, an event was considered to have oc-
curred if a patient died as a result of colorectal cancer; in
the second, death by any other cause was considered an
event. This allowed for an assessment of whether or not
changing colorectal cancer survival trends were consistent
with general survival trends. Censored values included pa-
tients alive at the last data collection and patients lost to
follow-up. In all analyses the effect of ethnicity on surviv-
al, while controlling for the variables stage at diagnosis
(local, regional, distant), age, sex, and year of diagnosis
(to control for any linear time trends existing within co-
horts), was assessed using a hierarchical approach in
which a model including ethnicity was compared to one
that did not. Age and year of diagnosis were treated as con-
tinuous variables, as examinations did not reveal any non-
linear associations.
Results
Tables 1 and 2 provide frequency and percentage distribu-
tion data for stage at diagnosis, age, sex, and cause of
death by ethnicity and cohort. The average ages for each
stage at diagnosis were 66.6 years for local, 65.9 years for
regional, and 65.5 years for distant. For each variable, sig-
nificant ethnic differences were observed. When com-
pared to the other ethnic groups, Hawaiians in all three
cohorts were diagnosed at a more advanced stage [Likeli-
hood Ratio χ2 (8) = 36.8, 25.0, and 46.0; p < .0001, p <
.01, and p < .0001 respectively] and were more likely to
have died from colorectal cancer (as opposed to death by
other causes or still alive) [Likelihood Ratio χ2 (8) = 36.5,
71.2, and 69.6; p < .0001 for all]. Hawaiians also were sig-
nificantly younger within cohorts 2 and 3 [Likelihood Ra-
tio χ2 (4) = 92.3 and 180.5; p < .0001 for both]. When
compared to the other ethnic groups, Filipinos had a sig-
nificantly higher proportion of males in all three cohorts
[Likelihood Ratio χ2 (4) = 140.1, 92.7, and 32.1; p < .0001
for all].
Figure 1 presents the survivor function plots (stratified by
ethnicity) for each cohort and for each cause of death cat-
egory (controlled for stage at diagnosis, year of diagnosis,
age, and sex). The corresponding five-year survivor esti-
mates with 95% confidence intervals are shown in Table
3, and the parameter estimates for each Cox regression
model are provided in Table 4. Unadjusted five-year sur-
vival rates for each ethnic group were 80.5% for Japanese,
79.4% for Caucasian, 78.8% for Chinese, 76.4% for Fili-
pino, and 72.5% for Hawaiian. The test of the validity of
the proportional hazards assumption with the variable
[loge(time)-0.52] indicated no violation [χ2 (1) = 0.13, p =
0.72].
When an event was considered death by colorectal cancer,
significant ethnic differences were found for all three co-
horts [Likelihood Ratio χ2 (4) = 20.0, 23.1, and 12.0; p <
.001, p < .001, and p < .05 respectively]. An examination
of the confidence intervals for cohort 1 indicated that Jap-
anese and Caucasian patients had significantly longer
five-year survival than Filipino and Hawaiian patients. For
the second cohort, the confidence intervals indicated that
Caucasians had a significantly longer survival time than
Filipinos; and in the third cohort, Hawaiians had signifi-
cantly shorter survival time than all other ethnic groups.
When an event was considered any death not caused by
colorectal cancer, significant ethnic differences were again
found for all three cohorts [Likelihood Ratio χ2 (4) = 46.3,
73.3, and 57.9; p < .0001 for all]. Confidence intervals in-
dicated that the Japanese always had a significantly higher
survival rate than at least one other ethnic group.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/5
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Results were largely consistent with our hypothesis, but
with one major exception: the persistently low Hawaiian
colorectal cancer survival in cohort 3. This unpredicted
finding led to post hoc analyses that were identical to the
previous Cox regression models, but included the availa-
ble treatment variables (surgery, chemotherapy, radiation,
and hormone therapy) as additional predictors. Table 5
provides the percentages of each ethnic group receiving a
given treatment by stage. With the inclusion of treatment
variables, ethnic differences were no longer significant in
the third cohort, but remained significant in the first two
[Likelihood Ratio χ2 (4) = 25.3, 29.1, and 8.2; p < .0001,
p < .0001, and p = .08 respectively]. See Figure 2.
Additionally, we tested the post hoc hypothesis that Ha-
waiians have lower survival because they were both
younger and diagnosed at a more advanced stage than the
other groups. If advanced disease is more aggressive in
young people, this could explain why the Hawaiians had
lower survival. An interaction term between age and stage
at diagnosis was created and added to the models run pre-
viously. However this interaction term did not show sta-
tistical significance, failing to support the post hoc
hypothesis.
At least for cohort 3, our data also allowed us to compare
the predictive value of the SEER staging variable (local, re-
gion, and distant) with that of the more comprehensive
TNM staging variable. TNM staging provided significantly
improved predictive value over SEER staging [Likelihood
Ratio χ2 (1) = 126.4; p < .0001]. However, inclusion of
TNM staging did not eliminate the Hawaiian ethnic dis-
parity in outcome [Likelihood Ratio χ2 (4) = 11.7, p <
.05], again suggesting that stage at diagnosis alone does
not account for the persistently low survival among
Hawaiians.
Discussion
With few exceptions, results clearly supported the stated
hypothesis that ethnic disparities in colorectal cancer sur-
vival have been diminishing over time. Figure 1, showing
the convergence of survival over time, best exemplifies
this. The one discrepancy in this overall trend is the un-
changed life expectancy for the Hawaiian group in cohort
3. A comparison with the survival curves for other causes
of death within cohort 3 reveals that this effect is specific
to colorectal cancer and does not reflect a general tenden-
cy for Hawaiians to die sooner.
One possible explanation for this is that Hawaiians were
not utilizing medical care to treat colorectal cancer to the
same degree as other ethnic groups. Our post hoc analyses
did demonstrate that ethnic disparities were no longer sta-
tistically significant after controlling for treatment differ-
Table 1: Frequency of Colorectal Cancer Cases Diagnosed in Hawaii from 1960–2000.
ETHNICITY Caucasian Japanese Hawaiian Filipino Chinese TOTAL
C O H O R T1 2 3 1 23123123123123
STAGE
local 318 588 994 403 901 1668 59 178 299 90 246 440 79 171 299 949 2084 3700
regional 338 671 712 500 945 1210 57 143 279 116 236 334 97 167 191 1108 2162 2726
distant 240 324 360 208 390 453 58 102 153 83 139 146 59 86 69 648 1041 1181
missing 78 122 168 62 68 106 11 14 37 12 34 60 11 20 22 174 258 393
AGE
< 65 545 649 804 600 1033 1026 107 256 417 153 227 359 121 153 154 1526 2318 2760
≥ 65 429 1056 1430 573 1271 2411 78 181 351 148 428 621 125 291 427 1353 3227 5240
SEX
male 488 935 1299 669 1392 1985 99 266 427 259 495 637 153 248 299 1668 3336 4647
female 486 770 935 504 912 1452 86 171 341 42 160 343 93 196 282 1211 2209 3353
DEATH
cr cancer 331 567 506 422 859 775 93 182 246 142 251 234 99 161 124 1087 2020 1885
other 537 810 636 607 839 764 82 167 156 129 284 248 122 196 127 1477 2296 1931
censored 106 328 1092 144 606 1898 10 88 366 30 120 498 25 87 330 315 1229 4184
TOTAL 974 1705 2234 1173 2304 3437 185 437 768 301 655 980 246 444 581 2879 5545 8000
Notes. Cohort relates years of diagnosis, where cohort 1 is 1960–1974, cohort 2 is 1975–1987, and cohort 3 is 1988–2000. Death relates cause of 
death information, where cr cancer indicates colorectal cancer, other indicates any other cause, and censored indicates alive or missing. Stage is SEER 
staging.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/5
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Figure 1
Estimated Survival versus Time (Years) by Ethnicity. Estimated survival (survivor functions) versus time (years) strati-
fied by ethnicity for each cohort (1960–1974, 1975–1987, and 1988–2000) and cause of death category, controlling for the 
effects of SEER stage at diagnosis, year of diagnosis, age, and sex are provided.
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Table 2: Percentages of Colorectal Cancer Cases Diagnosed in Hawaii from 1960–2000.
ETHNICITY Caucasian Japanese Hawaiian Filipino Chinese TOTAL
C O H O R T 123123123123123123
STAGE
local 32.6 34.5 44.5 34.4 39.1 48.5 31.9 40.7 38.9 29.9 37.6 44.9 32.1 38.5 51.5 33.0 37.6 46.3
regional 34.7 39.4 31.9 42.6 41.0 35.2 30.8 32.7 36.3 38.5 36.0 34.1 39.4 37.6 32.9 38.5 39.0 34.1
distant 24.6 19.0 16.1 17.7 16.9 13.2 31.4 23.3 19.9 27.6 21.2 14.9 24.0 19.4 11.9 22.5 18.8 14.8
missing 8.0 7.2 7.5 5.3 3.0 3.1 5.9 3.2 4.8 4.0 5.2 6.1 4.5 4.5 3.8 6.0 4.7 4.9
AGE
< 65 56.0 38.1 36.0 51.2 44.8 29.9 57.8 58.6 54.3 50.8 34.7 36.6 49.2 34.5 26.5 53.0 41.8 34.5
≥ 65 44.0 61.9 64.0 48.8 55.2 70.1 42.2 41.4 45.7 49.2 65.3 63.4 50.8 65.5 73.5 47.0 58.2 65.5
SEX
male 50.1 54.8 58.1 57.0 60.4 57.8 53.5 60.9 55.6 86.0 75.6 65.0 62.2 55.9 51.5 57.9 60.2 58.1
female 49.9 45.2 41.9 43.0 39.6 42.2 46.5 39.1 44.4 14.0 24.4 35.0 37.8 44.1 48.5 42.1 39.8 41.9
DEATH
cr cancer 34.0 33.3 22.6 36.0 37.3 22.5 50.3 41.6 32.0 47.2 38.3 23.9 40.2 36.3 21.3 37.8 36.4 23.6
other 55.1 47.5 28.5 51.7 36.4 22.2 44.3 38.2 20.3 42.9 43.4 25.3 49.6 44.1 21.9 51.3 41.4 24.1
censored 10.9 19.2 48.9 12.3 26.3 55.2 5.4 20.1 47.7 10.0 18.3 50.8 10.2 19.6 56.8 10.9 22.2 52.3
TOTAL 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Notes. Cohort relates years of diagnosis, where cohort 1 is 1960–1974, cohort 2 is 1975–1987, and cohort 3 is 1988–2000. Death relates cause of 
death information, where cr cancer indicates colorectal cancer, other indicates any other cause, and censored indicates alive or missing. Stage is SEER 
staging.
Table 3: Probabilities of Surviving Five Years Among Three Cohorts of Colorectal Cancer Patients
COHORT ETHNICITY CAUSE OF DEATH
Colorectal Cancer Other
1 1960–1974 Japanese .68 (.65 – .71) .79 (.77 – .82)
Caucasian .68 (.64 – .71) .71 (.67 – .74)
Chinese .61 (.54 – .69) .76 (.71 – .83)
Filipino .47 (.41 – .55) .69 (.62 – .76)
Hawaiian .48 (.39 – .59) .67 (.58 – .76)
2 1975–1987 Japanese .70 (.68 – .72) .86 (.84 – .88)
Caucasian .74 (.72 – .77) .77 (.75 – .80)
Chinese .73 (.69 – .78) .84 (.81 – .88)
Filipino .66 (.62 – .70) .77 (.74 – .81)
Hawaiian .67 (.62 – .72) .83 (.80 – .87)
3 1988–2000 Japanese .82 (.81 – .84) .81 (.79 – .83)
Caucasian .82 (.80 – .84) .75 (.73 – .78)
Chinese .82 (.79 – .86) .79 (.75 – .83)
Filipino .81 (.78 – .84) .76 (.72 – .80)
Hawaiian .73 (.69 – .77) .79 (.75 – .83)
Notes. Probabilities (with 95% confidence intervals) of surviving five years among three cohorts of colorectal cancer patients by ethnicity and cause 
of death are provided. Values reflect the estimates controlling for the effects of SEER stage at diagnosis, year of diagnosis, age, and sex.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/5
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ences. Interestingly, however, Hawaiians did not appear
to be receiving less treatment; and with respect to chemo-
therapy and radiation, appear to have been receiving more
than the other ethnic groups. One possible explanation
for this is that treatment is causing adverse effects and
death. Another is that doctors see prognostic signs of se-
vere disease that are not measured by our covariates, and
therefore prescribe more treatment. That is, Hawaiians
may have more advanced disease than staging alone
indicates.
The implications of these findings are important. If differ-
ential screening constitutes the primary reason for ethnic
survival disparities, it should be possible to achieve equal-
ly favorable outcomes in all ethnic groups. With the ex-
ception of the Hawaiians, the evidence presented here
reflects a convergence in terms of screening, medical care,
and colorectal cancer survival among all ethnic groups.
Further efforts are needed to examine why Hawaiians do
not follow the overall trend, and how to make improve-
ments. In this regard, a Native Hawaiian cancer network
called the Imi Hale is attempting, along with support from
the National Cancer Institute, to increase screening for
colorectal cancer in Native Hawaiians.[27]
One limitation of this study is that data are restricted to
the state of Hawaii. However, even though there are clear-
ly potential regional differences in ethnic patterns of sur-
vival, the results of this study could be important beyond
Hawaii. For example, in national studies, it has been
shown that African-Americans are less likely than others
to receive adjuvant chemotherapy.[28] Differential treat-
ment utilization may drive ethnic outcome disparities.
The role of individual patient choice and the role of com-
plicating co-morbid conditions in treatment selection
probably play some role, and another limitation of our
study is not having access to this information. In future
studies, however, we hope to elucidate the impact of such
factors.
To this end, an important area for future research is de-
tailed analysis of specific treatments received by cancer pa-
tients. For example, beginning in 1988 (the start of the
third cohort in the present study) colorectal cancer surviv-
al has been improved through the use of 5-fluorouracil-
leucovorin as adjuvant chemotherapy.[29] This factor, as
well as improving stage distribution through screening,
has undoubtedly contributed to the greatly improved
colorectal cancer survival rates in the third cohort. Unfor-
tunately, the HTR does not provide adequate detail with
Table 4: Determinants for Five-year Survival Among Three Cohorts of Colorectal Cancer Patients.
COHORT VARIABLE DEATH BY COLORECTAL CANCER DEATH BY OTHER CAUSES
β s.e. χ2(1) eβ β s.e. χ2(1) eβ
1 1960–
1974
Stage 1.28 .050 659.0* 3.61 0.35 .044 65.5* 1.42
Year -0.43 .071 36.6* 0.65 -0.04 .071 0.3 0.96
Age 0.18 .025 50.4* 1.20 0.56 .025 521.2* 1.75
Sex -0.08 .066 1.5 0.92 -0.28 .056 25.6* 0.75
2 1975–
1987
Stage 1.66 .037 2029.3* 5.25 0.29 .036 68.8* 1.34
Year -0.14 .064 4.8 0.87 0.05 .061 0.7 1.05
Age 0.16 .020 64.2* 1.17 0.70 .022 997.9* 2.01
Sex -0.13 .047 7.4 0.88 -0.35 .045 61.3* 0.71
3 1988–
2000
Stage 1.80 .037 2398.7* 6.07 0.37 .036 102.1* 1.44
Year -0.01 .052 0.1 0.99 0.37 .079 22.0* 1.45
Age 0.16 .021 58.6* 1.17 0.58 .023 616.2* 1.79
Sex -0.10 .048 4.7 0.90 -0.29 .048 37.5* 0.75
Notes. Determinants for five-year survival among three cohorts of colorectal cancer patients by cause of death are provided. All values were 
obtained using the method of partial maximum likelihood estimation in Cox regression. β is the regression coefficient, and is equivalent to the log 
of the hazard ratio. s.e. is the standard error of the regression coefficient and is used for calculating chi-square, which in turn is used for determining 
the statistical significance of β. χ2(1) is the chi-square value with one degree of freedom (each variable provides a single degree of freedom) and is 
calculated as (β/s.e.)2. eβ is the hazard ratio and is interpreted in the standard fashion. For Year (of diagnosis) and Age, the parameters reflect the 
estimated change per 10-year increment. Sex is coded with male as the control. An asterisk indicates significance at the .0001 level; none of the oth-
ers was significant within the experimentwise α-level set to .005.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/5
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respect to specific chemotherapy treatments, so this hy-
pothesis could not be examined here. However, future
studies incorporating expanded data sources should ex-
amine whether Hawaiians have been receiving adjuvant
5-FU-leucovorin to the same degree as others, and if not,
why not (e.g., access, informed choice with refusal of rec-
ommended treatment, or co-morbid disease).
Conversely, if Hawaiians receive apparently similar adju-
vant therapy (i.e., same agents, dosage, number of cours-
es, etc.), do they benefit to the same degree as others?
Also, do they show a similar degree of treatment compli-
ance? These issues may be of particular relevance, because
results from this study suggest that Hawaiians are equally
likely, if not more likely, to receive treatments.
Hawaiians have been reported to have relatively high rates
of diabetes, renal and vascular disease, and tend to be af-
flicted at a younger age. Perhaps an interaction between
cancer treatment and comorbid conditions is having a
negative effect on Hawaiians. We speculate that co-mor-
bid illness might play a role in treatment selection for
some individuals with colorectal cancer. Collection of
ICD-9 diagnosis codes from non-HRT sources with appro-
priate record linkage would allow us to study this.
Figure 2
Estimated Survival versus Time (Years) by Ethnicity. 
Estimated survival (survivor functions) versus survival time 
(years) stratified by ethnicity for the third cohort (1988–
2000) controlling for the effects of SEER stage at diagnosis, 
year of diagnosis, age, sex, and treatment are provided.
Table 5: Frequencies and Percentages of Treatments by SEER Stage and Ethnic Group for Cohort 3 (1988–2000).
STAGE ETHNICITY TREATMENT
Surgery Chemo Radiation Hormone
N%N%N%N%
Local Japanese 1613 96.9 98 5.9 49 2.9 0 0.0
Caucasian 947 95.5 90 9.1 58 5.9 4 0.4
Chinese 293 98.3 7 2.3 5 1.7 0 0.0
Filipino 425 96.6 29 6.6 25 5.7 1 0.2
Hawaiian 290 97.3 32 10.7 23 7.7 1 0.3
Regional Japanese 1190 98.4 581 49.2 173 14.4 11 0.9
Caucasian 685 96.3 281 40.7 123 17.4 3 0.4
Chinese 188 98.4 88 47.1 30 15.8 1 0.5
Filipino 326 98.2 124 37.6 56 16.9 0 0.0
Hawaiian 265 95.0 149 54.4 66 23.8 3 1.1
Distant Japanese 314 69.5 240 54.3 53 11.8 2 0.4
Caucasian 251 69.9 126 36.2 31 8.7 4 1.1
C h i n e s e4 26 0 . 93 45 0 . 81 01 4 . 5 1 1 . 5
Filipino 103 70.6 79 55.2 21 14.5 2 1.4
Hawaiian 107 70.4 86 57.7 32 21.1 2 1.3BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/5
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Other results from this study indicate that age at diagnosis
is another significant predictor of survival, with older in-
dividuals having a shorter life expectancy after diagnosis.
However, a comparison of hazard ratios by cause of death
showed that the values were much lower for death due to
colorectal cancer than for other causes. This suggests that,
while age is clearly related to overall survival, it is less rel-
evant to colorectal cancer survival. That is, colon cancer is
not more deadly for older individuals than for younger
ones. Similarly, sex appears to predict colorectal cancer
survival. A small beneficial effect was observed for women
when considering death due to colorectal cancer, but a
strong effect when considering death due to other causes.
The impact of co-morbid disease on survival might ex-
plain these age and gender differentials.
Stage at diagnosis represents the most important prognos-
tic variable. In this study the SEER staging system was used
so that identical analyses could be performed across all
three cohorts. However, for the most recent cohort (co-
hort 3), TNM staging clearly improved survival predic-
tions over the less comprehensive SEER staging. In future
studies, we will use TNM staging whenever possible.
Conclusions
This study provided longitudinal evidence in support of
non-biologic explanations for ethnic disparities in color-
ectal cancer survival. Specifically, the present analysis sug-
gests that observed ethnic differences result from
differential screening. In Hawaii, ethnic disparities in
colorectal cancer survival have narrowed considerably
over the past 30 years. However, Hawaiian patients did
not experience the same degree of improvement in surviv-
al as the other ethnic groups.
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